drugset
drugset / Trial / NCT00599755

Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)

NCT00599755 ↗

Phase 1 Completed 68 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelDiagnostic

Summary

This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small cell lung cancer (NSCLC).

Timeline

Start
2009-01-01
Primary completion
2010-06-10
Completion
2011-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 4 unknown —
Subject Carboplatin Small molecule 6 unknown —
Subject Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 85 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1250 mg/m2 Intravenous

Indications

non-small cell lung carcinoma